SEOUL – Lifex Biolabs, a US research-based pharmaceutical company, will work with Macrogen, a biotechnology company and genomic analysis expert in South Korea, to develop a treatment for Parkinson’s disease as part of their strategic partnership.
Macrogen said he would select a biomarker, based on DNA sequencing technology. A biomarker is a measurable indicator of the severity or presence of a disease state. In 2020, Macrogen made a strategic investment in the form of loans to Lifex, which is developing small molecule drugs to treat patients with neurodegenerative diseases.
Lyfex uses a candidate material introduced by Nanyang Technological University in Singapore as a biomarker linked to Parkinson’s disease, which is a progressive disorder of the nervous system that affects movement. The disease occurs when the dopamine-secreting nerve cells distributed in mesenteric melanoma die. Lifex, which has developed a new material that activates and protects dopamine-secreting neurons, aims to complete non-clinical research by 2023.
“We can increase competitiveness in the development of treatments for Parkinson’s disease based on Macrogen’s excellent DNA sequencing facilities, world-class DNA sequencing infrastructure and new technology from Macrogen. drug development of Lyfex, “said Lee Su-kang, CEO of Macrogen, pledging to actively pursue precision medicine to predict, diagnose and treat disease.
Macrogen is involved in a state pilot project to establish big data in biology. It is part of the so-called K-DNA project to support the development of new drugs, medical device products and the digital health industry. The two-year project involves establishing clinical information and genomic data on more than 20,000 people. Big Data in Biology helps explore the role of data-driven analysis in reaching logical conclusions to solve biological problems.
© Aju Business Daily & www.ajunews.com Copyright: All material on this site may not be reproduced, distributed, transmitted, posted, published or broadcast without permission of Aju News Corporation.